



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 8716**
Daiji NAKA et al. : Docket No. 2001-1797A
Serial No. 10/000,096 : Group Art Unit 1644
Filed December 4, 2001 : Examiner Not Yet Assigned

SPECIFIC ANTIBODY DIRECTED TO :
ACTIVE HEPATOCYTE GROWTH FACTOR
ACTIVATOR AND METHOD FOR USING
THE SAME

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of ☒ the references listed on attached form PTO-1449 and/or ☐ the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:

- b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Daiji NAKA et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/gtn
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
March 8, 2002

Sheet 1 of 1

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: March 8, 2002

ATTY DOCKET NO.
2001-1797A

SERIAL NO.
10/000,096

APPLICANT
Daiji NAKA et al.

FILING DATE
December 4, 2001

GROUP
1644

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|--------------------|----------|------------------|-------|----------|-------------------------------|
| | AA | 5,466,593 | 11/14/95 | Shimomura et al. | 435 | 219 | |
| | AB | 5,677,164 | 10/14/97 | Shimomura et al. | 435 | 226 | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO | |
|--|----|--------------------|---------|---------|-------|----------|-----------------------------|--|
| | AF | 5103670 | 4/27/93 | JP | | | abstract | |
| | AG | 6-153946 | 6/3/94 | JP | | | corresponds to AA and AB | |
| | AH | 6-153966 | 6/3/94 | JP | | | corresponds to AA and AB | |
| | AI | | | | | | | |
| | AJ | | | | | | | |

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | | | | | | |
|--|----|--|--|--|--|--|--|--|
| | AK | K. Miyazawa et al., "Molecular Cloning and Sequence Analysis of the cDNA for a Human Serine Protease Responsible for Activation of Hepatocyte Growth Factor", The Journal of Biological Chemistry, Vol. 268, No. 14, pp. 10024-10028 (1993). | | | | | | |
| | AL | T. Shimomura et al., "A novel protease obtained from FBS-containing culture supernatant, that processes single chain form hepatocyte growth factor to two chain form in serum-free culture", Cytotechnology 8: 219-229 (1992). | | | | | | |
| | AM | K. Miyazawa et al., "Activation of Hepatocyte Growth Factor in the Injured Tissues is Mediated by Hepatocyte Growth Factor Activator", The Journal of Biological Chemistry, Vol. 271, No. 7, pp. 3615-3618 (1996) | | | | | | |
| | AN | T. Shimomura et al., "Activation of the Zymogen of Hepatocyte Growth Factor Activator by Thrombin", The Journal of Biological Chemistry, Vol. 268, No. 30, pp. 22927-22932, (1993). | | | | | | |
| | | K. Miyazawa et al., "Molecular Cloning and Sequence Analysis of the Hepatocyte Growth Factor Activator from Human | | | | | | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.